AIMS/HYPOTHESIS: Elevated high-sensitivity C-reactive protein (hsCRP) concentrations indicate increased risk of future coronary events. The association between hsCRP and coronary vasoreactivity has not yet been examined in type 1 diabetic subjects. METHODS: We studied 18 young men who were non-smokers and who had uncomplicated type 1 diabetes. The diabetic subjects were divided into two groups, according to their median hsCRP concentration, as follows: (i) subjects with slightly elevated hsCRP (median 0.76 mg/l, range 0.47-4.73 mg/l, n=8); and (ii) subjects with low hsCRP (median 0.32 mg/l, range 0.11-0.35 mg/l, n=10). In addition we investigated 22 non-diabetic age-matched subjects (hsCRP: median 0.42 mg/l, range 0.11-1.31 mg/l). Resting myocardial blood flow and hyperaemic adenosine-stimulated flow during euglycaemic-hyperinsulinaemic clamp were determined using positron emission tomography and oxygen-(15)-labelled water. RESULTS: Diabetic subjects with slightly elevated hsCRP had significantly higher hsCRP concentrations than non-diabetic subjects (p=0.008). Resting myocardial blood flow was similar (NS) in diabetic subjects with slightly elevated hsCRP (0.79+/-0.19 ml.g(-1).min(-1)) or low hsCRP (0.81+/-0.15 ml.g(-1).min(-1)) and non-diabetic subjects (0.80+/-0.19 ml.g(-1).min(-1)). Adenosine infusion induced a significant increase in blood flow in all study subjects (p<0.001) but was blunted in diabetic subjects with slightly elevated hsCRP (3.42+/-0.61 ml.g(-1).min(-1)) when compared with diabetic subjects with low hsCRP (5.08+/-1.65 ml.g(-1).min(-1), p=0.02) or non-diabetic subjects (4.51+/-1.36 ml.g(-1).min(-1), p=0.04). Adenosine-stimulated flow was inversely correlated with hsCRP concentrations in all diabetic subjects (r=-0.70, p=0.001). CONCLUSIONS/ INTERPRETATION: In young subjects with uncomplicated type 1 diabetes, even slightly elevated hsCRP concentrations are associated with reduced coronary vasoreactivity.
AIMS/HYPOTHESIS: Elevated high-sensitivity C-reactive protein (hsCRP) concentrations indicate increased risk of future coronary events. The association between hsCRP and coronary vasoreactivity has not yet been examined in type 1 diabetic subjects. METHODS: We studied 18 young men who were non-smokers and who had uncomplicated type 1 diabetes. The diabetic subjects were divided into two groups, according to their median hsCRP concentration, as follows: (i) subjects with slightly elevated hsCRP (median 0.76 mg/l, range 0.47-4.73 mg/l, n=8); and (ii) subjects with low hsCRP (median 0.32 mg/l, range 0.11-0.35 mg/l, n=10). In addition we investigated 22 non-diabetic age-matched subjects (hsCRP: median 0.42 mg/l, range 0.11-1.31 mg/l). Resting myocardial blood flow and hyperaemic adenosine-stimulated flow during euglycaemic-hyperinsulinaemic clamp were determined using positron emission tomography and oxygen-(15)-labelled water. RESULTS:Diabetic subjects with slightly elevated hsCRP had significantly higher hsCRP concentrations than non-diabetic subjects (p=0.008). Resting myocardial blood flow was similar (NS) in diabetic subjects with slightly elevated hsCRP (0.79+/-0.19 ml.g(-1).min(-1)) or low hsCRP (0.81+/-0.15 ml.g(-1).min(-1)) and non-diabetic subjects (0.80+/-0.19 ml.g(-1).min(-1)). Adenosine infusion induced a significant increase in blood flow in all study subjects (p<0.001) but was blunted in diabetic subjects with slightly elevated hsCRP (3.42+/-0.61 ml.g(-1).min(-1)) when compared with diabetic subjects with low hsCRP (5.08+/-1.65 ml.g(-1).min(-1), p=0.02) or non-diabetic subjects (4.51+/-1.36 ml.g(-1).min(-1), p=0.04). Adenosine-stimulated flow was inversely correlated with hsCRP concentrations in all diabetic subjects (r=-0.70, p=0.001). CONCLUSIONS/ INTERPRETATION: In young subjects with uncomplicated type 1 diabetes, even slightly elevated hsCRP concentrations are associated with reduced coronary vasoreactivity.
Authors: M F Di Carli; D Bianco-Batlles; M E Landa; A Kazmers; H Groehn; O Muzik; G Grunberger Journal: Circulation Date: 1999-08-24 Impact factor: 29.690
Authors: C G Schalkwijk; D C Poland; W van Dijk; A Kok; J J Emeis; A M Dräger; A Doni; V W van Hinsbergh; C D Stehouwer Journal: Diabetologia Date: 1999-03 Impact factor: 10.122
Authors: M J Stevens; F Dayanikli; D M Raffel; K C Allman; T Sandford; E L Feldman; D M Wieland; J Corbett; M Schwaiger Journal: J Am Coll Cardiol Date: 1998-06 Impact factor: 24.094
Authors: H Laine; J Sundell; P Nuutila; O T Raitakari; M Luotolahti; T Rönnemaa; T Elomaa; P Koskinen; J Knuuti Journal: Heart Date: 2004-03 Impact factor: 5.994
Authors: H Laine; O T Raitakari; H Niinikoski; O P Pitkänen; H Iida; J Viikari; P Nuutila; J Knuuti Journal: J Am Coll Cardiol Date: 1998-07 Impact factor: 24.094
Authors: Sridevi Devaraj; Mohan R Dasu; Jason Rockwood; William Winter; Steven C Griffen; Ishwarlal Jialal Journal: J Clin Endocrinol Metab Date: 2007-11-20 Impact factor: 5.958
Authors: Venkatesh L Murthy; Masanao Naya; Courtney R Foster; Mariya Gaber; Jon Hainer; Josh Klein; Sharmila Dorbala; Ron Blankstein; Marcelo F Di Carli Journal: Circulation Date: 2012-08-23 Impact factor: 29.690